BioCentury | Jan 21, 2021
Product Development

Jan. 20 Quick Takes: AZ, Daiichi get Enhertu approvals in gastric, breast cancer; plus EdiGene, Merck, Oxford, BMS and Omeros

...CTX001 is in a Phase I/II trial, while Editas’ EDIT-301 is in preclinical development.FDA approves Merck’s...
BioCentury | Jan 21, 2021
Product Development

Merck KGaA’s bintrafusp alfa miss suggests there’s still more to learn about TGFβ

...Senior Editor The Phase III miss for Merck...
...can help overcome checkpoint resistance. On Wednesday, Merck...
...of development, said on a Wednesday investor call.Merck...
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

...autoimmune assets. First up for the company is a Phase IIb-ready Berger disease therapy from Merck...
...area he says is “underserved by science right now.”Vera in-licensed its first program, atacicept, from Merck...
...disease, or IgA nephropathy (IgAN), an orphan chronic kidney disease for which there are no approved therapies. Merck...
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...collaborations, including one with the U.K. on COVID-19. Celentano's track record includes vaccine-related roles with Merck...
BioCentury | Jan 15, 2021
Regulation

Jan. 14 Quick Takes: Lexicon rises on NDA timeline for heart failure program; plus: FDA COVID reports and updates from BeiGene, Merck, Bayer

...$650 million up front and up to $1.6 billion in milestones, plus royalties. Priority review for Merck’s...
...subject to comment. TARGETSSGLT1 – Sodium-glucose cotransporter 1SGLT2 – Sodium-glucose cotransporter 2 BC Staff Lexicon Pharmaceuticals Inc. Bayer AG Merck...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...terminated obicetrapib’s development in 2017 for strategic reasons, not long after a CETP readout from Merck...
...among CETP, LDL-C lowering and CV risk. Moreover, further clinical study of another CETP program, Merck’s...
...events that cardiologists believed would have led them to prescribe the compound over generic ezetimibe; Merck...
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...is in a randomized Phase I/II trial in combination with anti-PD-1 mAb Keytruda pembrolizumab from Merck...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

...more than 100,000 diverse strains isolated from across the globe and assembled by pharmas including Merck...
BioCentury | Jan 13, 2021
Product Development

On the back of mRNA vaccine validation, Moderna adds three infectious disease programs to pipeline

...the company as chief safety officer from Merck...
...where he was chief safety officer for Merck...
BioCentury | Jan 12, 2021
Deals

Sanofi joins the myeloid checkpoint movement with Biond deal

...activation.”Sanofi is at least the second pharma to enter the myeloid checkpoint space. In September, Merck...
Items per page:
1 - 10 of 10302
BioCentury | Jan 21, 2021
Product Development

Jan. 20 Quick Takes: AZ, Daiichi get Enhertu approvals in gastric, breast cancer; plus EdiGene, Merck, Oxford, BMS and Omeros

...CTX001 is in a Phase I/II trial, while Editas’ EDIT-301 is in preclinical development.FDA approves Merck’s...
BioCentury | Jan 21, 2021
Product Development

Merck KGaA’s bintrafusp alfa miss suggests there’s still more to learn about TGFβ

...Senior Editor The Phase III miss for Merck...
...can help overcome checkpoint resistance. On Wednesday, Merck...
...of development, said on a Wednesday investor call.Merck...
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

...autoimmune assets. First up for the company is a Phase IIb-ready Berger disease therapy from Merck...
...area he says is “underserved by science right now.”Vera in-licensed its first program, atacicept, from Merck...
...disease, or IgA nephropathy (IgAN), an orphan chronic kidney disease for which there are no approved therapies. Merck...
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...collaborations, including one with the U.K. on COVID-19. Celentano's track record includes vaccine-related roles with Merck...
BioCentury | Jan 15, 2021
Regulation

Jan. 14 Quick Takes: Lexicon rises on NDA timeline for heart failure program; plus: FDA COVID reports and updates from BeiGene, Merck, Bayer

...$650 million up front and up to $1.6 billion in milestones, plus royalties. Priority review for Merck’s...
...subject to comment. TARGETSSGLT1 – Sodium-glucose cotransporter 1SGLT2 – Sodium-glucose cotransporter 2 BC Staff Lexicon Pharmaceuticals Inc. Bayer AG Merck...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...terminated obicetrapib’s development in 2017 for strategic reasons, not long after a CETP readout from Merck...
...among CETP, LDL-C lowering and CV risk. Moreover, further clinical study of another CETP program, Merck’s...
...events that cardiologists believed would have led them to prescribe the compound over generic ezetimibe; Merck...
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...is in a randomized Phase I/II trial in combination with anti-PD-1 mAb Keytruda pembrolizumab from Merck...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

...more than 100,000 diverse strains isolated from across the globe and assembled by pharmas including Merck...
BioCentury | Jan 13, 2021
Product Development

On the back of mRNA vaccine validation, Moderna adds three infectious disease programs to pipeline

...the company as chief safety officer from Merck...
...where he was chief safety officer for Merck...
BioCentury | Jan 12, 2021
Deals

Sanofi joins the myeloid checkpoint movement with Biond deal

...activation.”Sanofi is at least the second pharma to enter the myeloid checkpoint space. In September, Merck...
Items per page:
1 - 10 of 10302